2024 Patient Advocacy Report Reveals Top Pharmaceutical Companies in Patient Support

The Advocate: Supporting the Patient Voice has released its 2024 US Focused Patient Advocacy Report, offering a comprehensive analysis of the pharmaceutical industry's engagement with patient advocacy organizations and professional societies. The report, made possible through sponsorship from various pharmaceutical companies, aims to foster improved healthcare outcomes for patients by identifying innovative collaboration strategies.

Johnson & Johnson (J&J) emerged as the top-ranked company for advocacy, securing first place in all five benchmarking categories. The report commends J&J for its transition from patient centricity to patient partnership, noting the company's willingness to collaborate beyond funding and its holistic approach to relationship-building with advocacy organizations.

Amgen demonstrated significant progress, advancing in four out of five benchmarking categories. Patient advocates praised Amgen for its innovative thinking and multi-level engagement with advocacy groups, emphasizing the company's efforts to understand and address patient needs in treatment advancement.

Pfizer maintained its strong position, ranking second in Advancing Patient Treatment and Patient/Professional Group Relations. The company received recognition for its commitment to obtaining patient perspectives for care advancement and its dedication to patient support and education.

Sanofi showed improvement across several measures, with patient advocates highlighting the company's exceptional patient engagement and its efforts to promote health equity through community-building initiatives among patient organizations.

The report also acknowledged other notable performances: AstraZeneca improved in Policy Support, Eli Lilly led in Neurology group rankings, Merck excelled with Non-disease Specific groups, and Bristol-Myers Squibb topped the Immunology group category.

This annual report serves as a vital tool for understanding the evolving relationship between patient advocates and the pharmaceutical industry. It aims to ensure that patients remain at the center of all healthcare decisions, from clinical settings to policy-making arenas.

The Advocate's research provides valuable insights for pharmaceutical advocacy teams, aids in the development of patient centricity programs, and offers guidance on incorporating the patient voice throughout a product's lifecycle. This information is crucial for pharmaceutical companies seeking to align their strategies with patient needs and improve overall healthcare outcomes.

As the healthcare landscape continues to evolve, reports like this play an essential role in shaping industry practices and fostering collaborations that ultimately benefit patients. By highlighting successful strategies and areas for improvement, the 2024 US Focused Patient Advocacy Report encourages pharmaceutical companies to enhance their patient advocacy efforts and strengthen their relationships with patient organizations.

For more information about the current report or previous editions, interested parties can visit www.TheBrooksGroupOnline.com.